Abstract
Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings.
| Original language | English |
|---|---|
| Pages (from-to) | 396-404 |
| Number of pages | 9 |
| Journal | Clinical and Applied Thrombosis/Hemostasis |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Apr 1 2018 |
Fingerprint
Keywords
- direct oral anticoagulant
- nonvalvular atrial fibrillation
- stroke
ASJC Scopus subject areas
- Hematology
Cite this
Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation : A Practical Guide for Neurologists. / Canavero, Isabella; Micieli, Giuseppe; Paciaroni, Maurizio.
In: Clinical and Applied Thrombosis/Hemostasis, Vol. 24, No. 3, 01.04.2018, p. 396-404.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation
T2 - A Practical Guide for Neurologists
AU - Canavero, Isabella
AU - Micieli, Giuseppe
AU - Paciaroni, Maurizio
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings.
AB - Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings.
KW - direct oral anticoagulant
KW - nonvalvular atrial fibrillation
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85042066354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042066354&partnerID=8YFLogxK
U2 - 10.1177/1076029617720068
DO - 10.1177/1076029617720068
M3 - Article
VL - 24
SP - 396
EP - 404
JO - Clinical and Applied Thrombosis/Hemostasis
JF - Clinical and Applied Thrombosis/Hemostasis
SN - 1076-0296
IS - 3
ER -